Epilepsy

Role of Extended-Release Formulations in Epilepsy

An Overview of the Epilepsy Treatment Paradigm

Parting Advice on Managing Patients With Epilepsy

Stimulation Techniques in Epilepsy: How Do We Choose?

Considerations for Nonmedication Therapy in Epilepsy

Epilepsy: Transitioning From Pediatric to Adult Care

Epilepsy: Recommendations on Discontinuing Therapy

The Cost of Nonadherence in Epilepsy Management

Extended Release Formulation's Role in Treating Epilepsy

Best Practices in Therapy Selection for Epilepsy

Appreciating the Expanding Armamentarium for Epilepsy

Epilepsy Management: Gauging Limitations of Guidelines

Further Establishing a Treatment Threshold in Epilepsy

When to Initiate Therapy in Patients With Epilepsy

An Unmet Need in Epilepsy? Diagnostic/Prognostic Biomarkers

Prominent Goals of Therapy in Epilepsy Management

Tools in the Diagnosis and Evaluation of Epilepsy

Improving Epilepsy Understandings: ILAE 2017 Classification

Evolving Knowledge of Epilepsy Incidence and Etiology

FDA Issues Final Policy Framework for RMAT Designated Therapies

Does Being Born Slightly Early or Slightly Late Affect Epilepsy Risk?

The framework consists of 2 documents that expand on the agency’s plans for its risk-based approach for describing drugs, devices, and biologics, including those designated as regenerative medicine advanced therapies.

infant baby neonate physician doctor pediatrician

Veronica Hackethal, MD

February 14th 2019

Zhibin Chen, PhD: Treatment Gap in Patients with Newly Diagnosed Epilepsy

Results of this Swedish study may help guide decisions about monitoring and induction of labor.

Zhibin Chen, PhD

February 13th 2019

Joseph Sullivan, MD: Efficacy of ZX008 in Dravet Syndrome

Despite accessibility to antiepileptic drugs in high-income settings, more than one-third of patients with newly diagnosed epilepsy were not treated or had delayed treatment.

Jenna Payesko

February 12th 2019

Using Focused Ultrasound for Medically Refractory Lobe Focal Onset Epilepsy

The director of the Pediatric Epilepsy Center at UCSF Benioff Children’s Hospital discussed the efficacy profile of ZX008, for which Zogenix recently submitted a new drug application to the FDA for the treatment of Dravet syndrome.

$Using Focused Ultrasound for Medically Refractory Lobe Focal Onset Epilepsy$

February 9th 2019

In Dravet Syndrome, ZX008 Shows Potential to Meet The Need for Treatments

The neurosurgeon at The Ohio State University Wexner Medical Center and lead investigator of the first-in-world trial spoke about the study’s goals and the potential of the treatment.

February 8th 2019

Updated AAN Guidelines on New Antiepileptic Drugs: 6 Key Recommendations

The executive vice president and chief medical officer of Zogenix spoke about what sets the fenfluramine agent apart and what clinicians need to know after its NDA submission.

Veronica Hackethal, MD

February 8th 2019

FDA Accepts NDA Submission of Cenobamate for Partial-Onset Seizures

Guidelines from the American Academy of Neurology now cover the use of third-generation antiepileptic drugs for patients with new-onset focal or generalized epilepsy.

Jenna Payesko

February 7th 2019

Zogenix Submits NDA for ZX008 for Dravet Syndrome

The initial phase 2 studies of cenobamate evaluated close to 1000 individuals, with efficacy demonstrated to the point that the FDA did not require additional efficacy studies.

February 7th 2019